November 29, 2023
(press release)
–
Novavax’s partner, SK bioscience,today announced that Novavax’s updated COVID-19 vaccine (NVX-CoV2601) has received Emergency Use Authorization from the Ministry of Food and Drug Safety in the Republic of Korea.Doses are available in market for use this vaccination season.InSouth Korea, SK bioscience and Novavax have a licensing agreement where SK bioscience has exclusive commercial rights to Novavax’s updated COVID-19 vaccine. Novavax’s updated COVID-19 vaccine is also authorized in the U.S.,the European Union and by the World Health Organization,and is under review in other markets.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.